Liraglutide attenuates aluminum chloride-induced Alzheimer’s disease in rats by modulating the oxLDL/LPA/LPAR1 pathway.

<b>Title</b><b>:</b><i> L</i><i>iraglutide attenuates aluminum chloride–induced Alzheimer’s disease in rats by modulating the oxLDL/LPA/LPAR1 pathway</i><b>Description</b><b>:</b> This dataset supports the manuscript currently under review, which investigates the neuroprotective effects of liraglutide in a rat model of Alzheimer’s disease induced by aluminum chloride (AlCl₃). The study highlights the modulation of the oxLDL/LPA/LPAR1/BACE1 pathway as a novel mechanism of action.<b>Contents</b><b>:</b>• Raw behavioral data (e.g., open field, Morris water maze, novel object recognition, etc.)• Biochemical and neurochemical assay results (GSH, MDA, AChE, ELISA data for oxLDL, LPA, LPAR1, BACE1)• Histopathological and immunohistochemical quantifications (e.g., NFTs % area, Aβ plaques/field, protein expression levels)• Statistical analysis outputs (SPSS/GraphPad Prism files if applicable)<b>Methods Summary</b><b>:</b> Data were generated using validated behavioral tests, ELISA, histopathology, and immunohistochemistry in male Sprague-Dawley rats. Treatments included AlCl₃, liraglutide, and donepezil over 45 days.<b>Ethics</b><b>: </b>All animal procedures were approved by the Research Ethics Committee of the Faculty of Pharmacy, Mansoura University (Code: 2022--175).This dataset is under embargo to align with the peer review process. It will be made publicly available upon manuscript acceptanc<b>License</b><b>:</b> CC-BY 4.0